Medical Licensing (MD/DO) · Independent exam preparation
EBSQ Examination in Transplant Surgery: Selective Preparation Guide Study Guide
Practise donor selection, operative planning and graft-complication decisions across all four EBSQ transplant surgery modules with focused concepts and original drills.
By CertMedbry · Updated 19 October 2026
Practise deciding whether donation is appropriate, how anatomy changes implantation, and when graft dysfunction requires imaging, biopsy or urgent surgery. This selective guide develops 60 clinical concepts across the four published modules. The official UEMS curriculum defines the full examination scope, including topics beyond this guide; use it to complete preparation for each module you select.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
What qualification does this examination lead to?
The official identity is the EBSQ Examination in Transplant Surgery, administered through the UEMS Section of Surgery, European Board of Surgery and Division of Transplant Surgery. Successful eligibility assessment and examination lead to Fellow of the European Board of Surgery, FEBS, in Transplant Surgery. This is a specialist surgical qualification. The issuer states that the fellowship itself has no automatic legal recognition in the European Union or another country.
Which modular pathway does this guide cover?
This guide covers the four-module curriculum: Multi-organ retrieval, Kidney transplantation, Pancreas transplantation and Liver transplantation. Candidates can seek accreditation in one or more modules, so concentrate examination practice on the modules selected for your application. Heart and lung transplantation certification belongs to a separate UEMS Section of Thoracic Surgery process. The honorary diploma described elsewhere on the curriculum page is a separate recognition route, not this examination pathway.
Transplant Surgery EBSQ Examinations · Transplant Surgery Curriculum
How many questions and stations are used, and how long do they last?
The issuer page checked on 19 October 2026 specifies two on-site stations for each selected module, with nine questions per station. Each station lasts 30 minutes, giving 18 questions and 60 minutes of station time per module under the standard arrangement. The examination is conducted in English. Two different examiners are specified for each module's stations; an additional examiner may occasionally be present.
How are stations scored and passed?
Each station offers a maximum of 45 points: nine questions, each worth up to five points. Candidates must obtain at least 27 points in each of the two stations of the same module. A higher score in one station therefore does not establish a pass for an under-threshold companion station. Following score review, the examination board may occasionally offer a third station for that module.
Are there pretest items, adaptive delivery or published item-style proportions?
The published format describes examiner-led, on-site stations and assigns a maximum score to each of the nine questions per station. It does not identify a separate unscored or pretest question count, describe computer-adaptive delivery, or publish proportions for particular station question styles. The four-option questions here are an independent study format, not a reproduction of the station format.
Which blueprint version and domain weights apply?
The official curriculum was checked on 19 October 2026. It displays four modules but no revision identifier, effective date or numerical domain weights. This guide therefore uses an editorial allocation of 15 concepts, five questions and five flashcards per module. Equal coverage does not imply official weighting. The published curriculum, rather than these 60 selected concepts, remains the full scope for each selected module.
Does the listed Cambridge date establish the next examination?
The issuer page still labels 11 September 2026 in Cambridge as the next examination. That date had already passed by 19 October 2026, so it does not establish a future sitting. Obtain a current sitting announcement and application deadline directly from the issuer before making arrangements.
How should the dates and jurisdictions of clinical references be interpreted?
Clinical references support the teaching points separately from the examination curriculum. The EAU 2026 edition reprints its 2024 guideline; the KDIGO living-donor guideline is from 2017, the KDIGO recipient guideline is from 2009 despite its later upload path, and the EASL liver guideline is from 2024. The death-determination examples explicitly use the 2025 UK Code, while PHS infectious surveillance examples use the 2020 U.S. guideline.
EAU Renal Transplantation Guidelines — Summary of Changes · Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors · KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · EASL Clinical Practice Guidelines on liver transplantation, 2024 · A Code of Practice for the diagnosis and confirmation of death: 2025 update · Assessing Solid Organ Donors and Monitoring Transplant Recipients for HIV, HBV, and HCV Infection — U.S. Public Health Service Guideline, 2020
Independent educational material for a specialist surgical qualification leading to FEBS in Transplant Surgery. The questions are original single-best-answer learning drills; the official examination uses examiner-led stations. These materials do not predict examination success.
Outline used: Currently published, undated UEMS Transplant Surgery Curriculum, consulted 2026-10-10. No revision identifier or effective date is displayed. The assigned workbook label maps to the official EBSQ Examination in Transplant Surgery, leading to FEBS in Transplant Surgery; the canonical slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Multi-organ retrievalnot stated
1.How does organ-specific assessment refine donor suitability?
Donor suitability has both a whole-person component and a separate assessment of each proposed organ. Infection, malignancy, physiological instability and treatment history affect overall risk, while anatomy, function and tissue injury influence individual graft use. A kidney biopsy is one contribution to this assessment, rather than an isolated acceptance rule. The discriminating decision is whether the organ's combined risks are acceptable for the intended recipient, considering clinical findings and preservation information together.
Apply it
An older donor has satisfactory kidney perfusion but a biopsy reporting chronic changes. You integrate renal function, comorbidities, sampling quality and recipient circumstances before deciding whether either kidney is appropriate, rather than rejecting both from one histological percentage.
Common pitfall: A reassuring donor age or one adverse biopsy feature cannot independently establish suitability. Whole-donor and organ-specific findings may point in different directions.
2.Why can negative donor virology leave a transmission risk?
An infection acquired shortly before donation may remain below the detection threshold of available tests. Nucleic acid testing shortens the interval before detection compared with antibody testing, but does not abolish it. Under the 2020 U.S. PHS framework, recent exposure history therefore remains relevant alongside laboratory results. A negative result supports risk assessment; it does not justify describing transmission as impossible or abandoning the recipient's planned post-transplant surveillance.
Apply it
A donor's HIV, HBV and HCV nucleic acid tests are negative, but a recent exposure is documented. You explain the residual window-period risk, assess the recipient's benefit and ensure that the surveillance plan remains explicit.
Common pitfall: Treating negative nucleic acid testing as proof of zero risk confuses test sensitivity after detectable infection with exclusion of a very recent acquisition.
3.How are aortic perfusion, venous venting and organ removal coordinated?
The TSANZ guidance describes a sequence for abdominal organ recovery after neurological determination of death. Expose the aorta, cava, renal vein junctions and superior mesenteric artery, identify both ureters and check for low accessory renal arteries before choosing the infrarenal cannulation site. After anticoagulation and secure intraluminal cannulation, coordinate aortic cross-clamping, venous decompression and cold perfusion with the thoracic team. Without thoracic organ recovery, supracoeliac clamping occurs simultaneously with or immediately after venous venting. Add topical cooling around the liver, kidneys and pancreas. The guidance describes liver-pancreas removal en bloc, followed by kidney removal and vessel recovery, with separation and perfusion assessment on the cold back table. Circulatory-death donation requires rapid access and perfusion without the preceding warm dissection.
Apply it
Before cross-clamping, confirm cannula position, the planned venous vent and readiness of every participating team. During kidney removal, identify accessory arterial origins, preserve caval tissue for the right renal vein and retain vascularised proximal periureteric tissue.
Common pitfall: An arterial cannula alone does not establish effective preservation: venous drainage, cooling and coordinated timing also matter. Blind cannulation or aortic division can injure an unrecognised low renal artery.
TSANZ_SurgicalTechniqueForDeceasedDonorABDO_Version-11_02FINAL.pdf · EAU Guidelines on Renal Transplantation — The Guideline
4.When should recipients undergo PHS viral surveillance?
The 2020 U.S. PHS guideline recommends HIV, HBV and HCV nucleic acid testing at four to six weeks after transplantation, irrespective of whether the donor met specified risk criteria. Baseline testing helps distinguish pre-existing recipient infection from a new event. Testing immediately after implantation cannot replace later testing because newly acquired infection may not yet be detectable. The guideline also advises heightened awareness of delayed HBV infection in liver recipients and consideration of additional HBV testing.
Apply it
A recipient had negative baseline results and received an organ from a donor without identified exposure criteria. In a service following the 2020 U.S. PHS guideline, you still arrange the specified four-to-six-week nucleic acid surveillance.
Common pitfall: Restricting surveillance to labelled donor-risk groups misses the guideline's universal recipient-testing principle. The stated timing belongs to U.S. PHS guidance, not every jurisdiction.
5.How does traceability limit donor-derived infection harm?
A possible donor-derived infection has implications beyond the first affected recipient. Linking the donor, transplanted organs, stored specimens and recipient centres permits rapid investigation of a shared exposure. Timely notification can trigger testing and treatment in other recipients before symptoms develop. The clinical clue is an unexpected infection after transplantation with a plausible donor connection. Investigation should preserve accurate identifiers and timelines while considering alternative recipient-acquired sources rather than prematurely declaring transmission proven.
Apply it
One kidney recipient develops unexpected hepatitis after transplantation. You urgently activate the established notification pathway, identify the liver and other kidney recipient centres, and assemble baseline results and donor specimens for a coordinated investigation.
Common pitfall: Managing only the symptomatic recipient loses the opportunity to protect others. A suspected link warrants investigation and communication before definitive proof is available.
6.Why must depressant drug effects be excluded before neurological death testing?
Sedatives and other depressant drugs can suppress responses needed for neurological death determination. The 2025 UK Code requires reversible confounding effects to be excluded before clinical findings are relied upon. Clearance depends on the drug, exposure, temperature and organ function, so a fixed interval after stopping an infusion may be inadequate. The decisive distinction is between absent responses caused by irreversible brain failure and absent responses that remain potentially attributable to a reversible pharmacological effect.
Apply it
A ventilated patient has absent brainstem responses after prolonged sedation and develops renal impairment. Under the UK Code, you reassess possible residual drug activity and prerequisites before accepting the examination as evidence for neurological death.
Common pitfall: Absent responses during plausible residual sedation do not become valid solely because the structural brain injury is severe or organ donation would be beneficial.
A Code of Practice for the diagnosis and confirmation of death: 2025 update
7.How do neurological and circulatory criteria establish death differently in adults under the 2025 UK Code?
The 2025 UK Code requires an established devastating brain injury and exclusion of confounders before neurological testing. Two complete sets of clinical tests are required, each including absent brainstem responses and an apnoea test. Each adult apnoea test starts with PaCO2 at least 5.3 kPa, demonstrates no respiratory effort for at least five minutes, and ends with PaCO2 at least 8.0 kPa, a rise of at least 2.7 kPa and arterial pH below 7.3. With chronic carbon dioxide retention, start at or above the known chronic or typical baseline while retaining the rise and endpoint requirements. Preoxygenate and maintain oxygenation with 100% oxygen and CPAP during disconnection, with cardiovascular stability. Stop for respiratory effort, significant cardiovascular instability despite support, significant desaturation despite oxygen and CPAP, or an unstable arrhythmia. Circulatory determination instead requires continuous unconsciousness, apnoea and circulatory arrest throughout a minimum five-minute assessment, followed by confirmation of absent pupillary and corneal reflexes and no motor response to supraorbital pressure.
Apply it
Assess pupillary, corneal, vestibulo-ocular, motor, gag and cough responses before apnoea testing. Restore appropriate blood gases and baseline physiology before the second complete set. An aborted or incomplete apnoea test does not establish the required result.
Common pitfall: One complete neurological examination is insufficient. Five minutes without breathing is also insufficient unless all blood-gas endpoints are met. A five-minute circulatory assessment cannot substitute for neurological testing.
A Code of Practice for the diagnosis and confirmation of death: 2025 update
8.Why does maintaining donor perfusion protect potential grafts?
Organs need adequate circulation and oxygen delivery until preservation begins. Hypotension, hypoxaemia and major fluid or electrolyte disturbances can add injury to otherwise usable organs. Donor management therefore requires repeated physiological assessment and treatment directed at the cause of instability, rather than assuming that an organ with previously normal function remains unaffected. For kidneys, assessment of perfusion and the subsequent ischaemic burden contributes to the overall appraisal of likely graft function.
Apply it
A donor's urine output falls during sustained hypotension. You review circulation, oxygenation, fluid balance and biochemical changes with the intensive-care team, then communicate the episode and its duration to the receiving kidney team.
Common pitfall: An earlier normal creatinine does not exclude injury developing during later instability. Urine output also needs interpretation alongside perfusion and the broader physiological picture.
EAU Guidelines on Renal Transplantation — The Guideline · Transplant Surgery Curriculum
9.How does circulatory-death donation change the ischaemia assessment?
Donation after circulatory death can expose organs to warm hypoperfusion before cold preservation. Injury therefore depends on more than the duration of cold storage. Relevant observations include the physiological decline before arrest, the interval without circulation and the preservation method subsequently used. Time definitions vary between protocols, so an accurately labelled physiological timeline is more useful than an unexplained single duration. Acceptance requires organ-specific interpretation; the donor pathway alone neither guarantees nor excludes acceptable function.
Apply it
Two kidneys have identical cold-storage times, but one followed prolonged hypotension before circulatory arrest. You distinguish their warm-ischaemic histories and review preservation findings before assuming that their expected early function is equivalent.
Common pitfall: Comparing cold times alone hides earlier warm injury. An unqualified warm-ischaemia figure is also difficult to interpret without knowing its start and end definitions.
EAU Guidelines on Renal Transplantation — The Guideline · EASL Clinical Practice Guidelines on liver transplantation, 2024
10.Why does cold preservation reduce injury without eliminating it?
Cooling reduces metabolic demand while an organ is separated from its normal circulation. Preservation solution and controlled handling support this interval, but hypothermia does not make the organ metabolically inactive or prevent all ischaemic injury. The practical objective is effective preservation with avoidable delays minimised. A well-cooled graft can still develop delayed function, particularly when donor injury and warm ischaemia have already reduced its reserve. Preservation quality and elapsed time therefore require interpretation together.
Apply it
A receiving team expects a prolonged transport interval for a kidney with additional donor risk factors. You review the preservation strategy and coordinate readiness for implantation, recognising that adequate cooling does not make further delay harmless.
Common pitfall: Cold storage is a protective intervention, not an unlimited holding state. A technically successful implant cannot reverse every injury accumulated before reperfusion begins.
EAU Guidelines on Renal Transplantation — The Guideline · Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
11.What did the paired-kidney preservation trial establish?
The original randomised deceased-donor kidney study compared hypothermic machine perfusion with static cold storage using paired kidneys. Machine perfusion reduced delayed graft function, defined in that study as dialysis during the first post-transplant week. That definition describes a clinical outcome rather than a specific histological diagnosis. The finding supports a preservation benefit in the studied setting, but does not mean every perfused kidney functions immediately or that a machine measurement alone can determine acceptance.
Apply it
A perfused kidney recipient requires dialysis for severe hyperkalaemia on day two. You classify the event according to the trial's delayed-function endpoint while continuing to investigate perfusion, obstruction and parenchymal causes of poor graft function.
Common pitfall: A reduction in delayed graft function is not its elimination. The dialysis-based endpoint also cannot, by itself, distinguish ischaemic injury from rejection or obstruction.
Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
12.How is voluntary living donation protected during consent?
Living donation exposes a person to risk without treating disease in that donor. KDIGO therefore emphasises understandable information, assessment of voluntariness and freedom to withdraw. Discussion includes perioperative harms, longer-term uncertainty, alternatives for the recipient and the limits of individual risk prediction. The key cue is whether the donor can make an informed decision without pressure. A private assessment can reveal concerns that would remain hidden when the intended recipient or family speaks for the donor.
Apply it
A prospective donor agrees enthusiastically in front of relatives but expresses reluctance in private. You explore coercion and understanding, support an unpressured decision and protect confidentiality rather than treating the family discussion as definitive consent.
Common pitfall: A favourable medical evaluation does not establish valid consent. Recipient urgency cannot remove the donor's freedom to decline or withdraw from donation.
Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
13.Which kidney should a living donor retain?
Kidney-side selection combines donor safety, relative renal function and operative anatomy. When meaningful asymmetry or an abnormality exists, the donor's long-term interests guide the choice; retaining the better-functioning kidney is an important principle. Vascular multiplicity, venous length and other anatomical findings affect surgical planning, but technical convenience for implantation is not the sole objective. A suitable donation plan must remain acceptable for both donor nephrectomy and reconstruction of the donated organ.
Apply it
Imaging shows unequal renal function and more complex vessels on the less functional side. You assess whether that kidney can be donated safely and reconstructed, rather than automatically removing the technically simpler, better-functioning kidney.
Common pitfall: Choosing a side solely for a longer vein can overlook donor renal reserve. Anatomical complexity requires planning rather than an automatic preference in either direction.
Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors · EAU Guidelines on Renal Transplantation — The Guideline
14.Which hepatic arterial variants change preservation and splitting decisions?
A replaced left hepatic artery arises from the left gastric artery and passes through the lesser omentum to replace conventional left hepatic inflow; an accessory artery supplements conventional supply. TSANZ guidance specifically warns against injuring either variant during division of the gastrohepatic omentum. Preserve the origin and useful length before dividing adjacent gastric vessels. Segment IV can receive variable contributions from both hepatic arterial systems, as demonstrated by the [original cadaveric anatomical study](https://pmc.ncbi.nlm.nih.gov/articles/PMC5396263/). An adult-child split retaining segment IV with the extended right graft must preserve its actual arterial supply. A right hepatic artery arising from the superior mesenteric artery also requires a shared liver-pancreas plan: TSANZ describes preserving maximum hepatic arterial length and an anatomy-dependent reconstruction to the gastroduodenal artery stump.
Apply it
Map a left gastric-origin hepatic artery before dividing the lesser omentum. If a right hepatic artery arises from the superior mesenteric artery, agree its division with both organ teams, preserving reconstructable hepatic and pancreatic arterial ends. Identify segment IV branches before a planned split.
Common pitfall: A conventional right hepatic artery does not make a replaced left artery expendable. Segmental labels do not establish arterial territories, and dividing a shared arterial origin without a reconstruction plan can compromise either graft.
TSANZ_SurgicalTechniqueForDeceasedDonorABDO_Version-11_02FINAL.pdf · EASL Clinical Practice Guidelines on liver transplantation, 2024
15.How do allocation rules and individual risk assessment interact?
Allocation governs fair access to scarce organs, while clinical assessment determines whether a particular offer is appropriate for a particular recipient. These functions interact but are not interchangeable. A high position on a waiting list does not remove contraindications or eliminate the need for informed discussion of organ-specific risk. The UEMS curriculum includes allocation ethics and multidisciplinary practice; actual entitlement and priority depend on the relevant allocation system rather than a universal European numerical rule.
Apply it
An organ offer reaches a highly prioritised candidate who has developed a new serious infection. You reassess current suitability with the multidisciplinary team and apply the allocation system's procedures instead of assuming that priority mandates implantation.
Common pitfall: Priority establishes an allocation position, not a guarantee of current clinical suitability. Conversely, personal preference cannot replace the applicable rules for fair allocation.
Transplant Surgery Curriculum · EASL Clinical Practice Guidelines on liver transplantation, 2024
Kidney transplantationnot stated
16.How should preoperative electrolyte and volume problems be corrected?
A kidney candidate may arrive with hyperkalaemia, fluid overload or acid-base disturbance that makes anaesthesia unsafe. EAU guidance supports dialysis or conservative measures according to the abnormality and the likelihood of immediate graft function. Routine dialysis simply because transplantation is imminent is not indicated. The discriminating assessment is whether correction is necessary and how to achieve it without avoidable hypotension or delay, especially when the offered kidney has a substantial risk of delayed function.
Apply it
A candidate arrives for transplantation with marked hyperkalaemia and pulmonary congestion. You coordinate correction before anaesthesia, considering dialysis and its haemodynamic effects rather than relying on the new kidney to resolve the abnormalities immediately.
Common pitfall: Neither automatic preoperative dialysis nor automatic avoidance is appropriate. The decision follows the actual electrolyte, volume and acid-base problem and expected graft function.
17.What GFR findings guide living kidney donor acceptance?
The 2017 KDIGO guideline recommends confirming renal function rather than relying on a single creatinine estimate. A GFR of at least 90 mL/min/1.73 m² is acceptable from the renal-function perspective, whereas a GFR below 60 should preclude donation. Values from 60 to 89 require individualised assessment against the programme's acceptable risk threshold. Age, comorbidity and the rest of the donor profile matter; meeting a GFR threshold does not complete the entire donor evaluation.
Apply it
A donor candidate has a confirmed GFR of 76 mL/min/1.73 m². You assess the full demographic and health profile and the programme's risk threshold rather than declaring the result either an automatic acceptance or an absolute exclusion.
Common pitfall: A normal serum creatinine can conceal reduced filtration. Conversely, the intermediate KDIGO GFR range calls for individual assessment rather than a single universal decision.
Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
18.How does albumin excretion affect living donor assessment?
Albuminuria provides information about renal injury that GFR alone may miss. KDIGO recommends screening and confirming albumin excretion appropriately. An albumin excretion rate below 30 mg/day is acceptable from this perspective; more than 100 mg/day should preclude donation. The intermediate range requires individualised assessment. These thresholds refer to albumin excretion, not an interchangeable total-protein value. A potentially transient abnormal result should be interpreted in context before a durable donor decision is made.
Apply it
A donor has preserved GFR but a confirmed albumin excretion rate of 120 mg/day. You recognise a separate contraindicating renal-risk finding rather than accepting the donor because filtration remains within the normal range.
Common pitfall: Preserved filtration does not cancel albuminuria. Confusing albumin excretion with total urinary protein can also apply the guideline's thresholds to the wrong measurement.
Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
19.When can paired donation address an incompatible living donor?
An intended donor may be medically suitable but immunologically incompatible with the intended recipient. Paired donation seeks a different donor-recipient combination that permits compatible transplantation, avoiding the assumption that the original pair must either proceed unchanged or abandon living donation. KDIGO recommends counselling about available strategies, including paired donation and relevant incompatible-transplant options. The key distinction is between donor medical suitability and suitability for the particular recipient; solving compatibility does not remove the donor's independent assessment requirements.
Apply it
A healthy donor cannot donate directly because of ABO incompatibility. You discuss paired donation alongside locally available alternatives, explaining that another compatible pairing may preserve a living-donation opportunity without using the original incompatible match.
Common pitfall: ABO incompatibility does not automatically exclude all living-donor pathways. Paired donation also does not make a medically unsuitable donor acceptable for another recipient.
Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
20.Why are ABO compatibility and crossmatching separate assessments?
ABO testing assesses blood-group compatibility, while crossmatching investigates recipient reactivity against donor cells. A recipient may be ABO-compatible yet have clinically important donor-reactive HLA antibodies after sensitising events such as transplantation, transfusion or pregnancy. Preformed antibodies can injure graft endothelium rapidly after reperfusion. The decisive principle is that one reassuring compatibility result does not substitute for the others. Antibody history, donor-specific antibodies and the applicable crossmatch method require integrated interpretation before implantation.
Apply it
A previously transplanted recipient is ABO-compatible with a new donor but has a positive donor-cell crossmatch. You investigate the immunological risk instead of proceeding on the basis that matching blood groups have established compatibility.
Common pitfall: A good HLA match or compatible ABO group does not exclude donor-reactive antibodies. Historical sensitisation remains relevant even when the current clinical condition is stable.
21.How is the kidney implantation site chosen?
For most first or second single-kidney transplants, EAU guidance describes an extraperitoneal approach to an iliac fossa. Site selection considers recipient vessels, previous surgery, available space and the lie of the graft's vessels and ureter. There is no general requirement to place every donor kidney on one particular side. The operative goal is adequate inflow and outflow with an unobstructed urinary reconstruction, avoiding tension, twisting and compression when the graft reaches its final position.
Apply it
A candidate has severe vascular calcification on one side and a previous operation on the other. You review imaging and operative access to choose a workable implantation plan, rather than selecting the side solely from donor kidney laterality.
Common pitfall: A familiar side is not automatically the safest site. Assess the final graft position because an acceptable open-field anastomosis may kink after positioning.
22.How can a short deceased-donor right renal vein be extended?
The right renal vein can be too short for a tension-free venous anastomosis. EAU guidance describes back-table lengthening with donor inferior vena caval tissue when required for a deceased-donor right kidney. The purpose is reliable venous outflow without traction or distortion. Assessment includes the vein, its branches and the intended graft orientation. This option depends on available donor tissue; living-donor reconstruction requires different planning and cannot assume that a caval segment accompanies the kidney.
Apply it
At bench preparation, a deceased-donor right kidney has insufficient venous length for the intended position. A suitable attached caval segment is available, so you consider constructing an extension before implantation rather than accepting tension.
Common pitfall: The right-sided label alone does not mandate extension. Conversely, pulling a short vein into position can jeopardise outflow even when the arterial anastomosis appears satisfactory.
23.Why must periureteric tissue be preserved?
The transplant ureter depends on its retained graft-associated blood supply after separation from the donor. EAU guidance therefore emphasises preserving the peripelvic and proximal periureteric tissue in the golden triangle. Excessive stripping can injure the small vessels that sustain the ureter, increasing the risk of ischaemia, leakage or later narrowing. The useful operative distinction is between necessary preparation for a sound anastomosis and unnecessary skeletonisation undertaken merely to produce a visually clean ureter.
Apply it
During bench preparation, an assistant proposes removing the remaining soft tissue around the proximal ureter. You preserve the vascularised tissue and reassess the required ureteric length before constructing the urinary anastomosis.
Common pitfall: A longer, extensively dissected ureter is not necessarily safer. Apparent anastomotic security cannot compensate for an ischaemic segment that later breaks down.
24.Which findings distinguish a urinary leak from a lymphocele?
A postoperative fluid collection can represent urine, lymph, blood or infection. Urinary leakage is supported by the clinical timing, reduced bladder urine, imaging and collection-fluid creatinine substantially above serum. A lymphocele has a different source and should not be diagnosed from location alone. Management must address the urinary defect and drainage or decompression requirements, with reconstruction when necessary. The key decision is to identify what the fluid represents before treating every collection as a generic postoperative cavity.
Apply it
A recipient develops increasing clear drain output and falling bladder urine. The drain-fluid creatinine is far above the serum concentration. You investigate a urinary leak and its location rather than labelling the collection a lymphocele.
Common pitfall: Clear fluid is not diagnostic of lymph. Draining a urinoma without addressing the leak or obstruction can leave the underlying problem and infection risk unresolved.
25.When does abrupt graft dysfunction suggest a vascular emergency?
Sudden loss of urine after initial graft function, especially with graft pain or swelling, should raise concern for arterial or venous compromise. Urgent Doppler assessment can identify absent flow or patterns suggesting impaired venous drainage. Renal-vein thrombosis may produce reversed arterial diastolic flow, although findings require clinical interpretation. The priority is rapid surgical assessment when vascular compromise is suspected, because delay can eliminate salvage opportunities. Routine biopsy is not the first response to a threatened blood supply.
Apply it
On the first postoperative day, a previously functioning graft becomes painful and anuric. Doppler shows absent venous flow with reversed arterial diastolic flow. You immediately involve the transplant surgeon for suspected venous thrombosis.
Common pitfall: Attributing abrupt anuria to routine delayed function can miss a surgically treatable emergency. A biopsy cannot restore a thrombosed or mechanically compromised graft circulation.
26.How should delayed kidney graft function be investigated?
Dialysis during the first week is a common research definition of delayed graft function, but it does not identify the cause. Assessment begins with haemodynamics, fluid status, ultrasound and exclusion of vascular or urinary complications. Parenchymal causes include ischaemic injury and rejection, which can coexist. The 2009 KDIGO recipient guideline supports biopsy during delayed function because serum creatinine and dialysis requirements cannot reliably distinguish these processes. Ongoing monitoring must therefore test the working diagnosis rather than simply await recovery.
Apply it
A deceased-donor recipient remains dialysis-dependent despite adequate circulation and patent graft vessels. You review reversible causes and arrange appropriate graft assessment, including biopsy when indicated, instead of assuming prolonged ischaemic injury is the only explanation.
Common pitfall: The delayed-function label is an outcome description, not a tissue diagnosis. Presumed ischaemic injury should not prevent investigation for rejection or technical problems.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients · Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
27.When does persistent creatinine elevation require graft biopsy?
Persistent, unexplained creatinine elevation warrants investigation of parenchymal graft injury after reversible or structural explanations have been assessed. The 2009 KDIGO recipient guideline recommends biopsy for this pattern. Volume depletion, obstruction and excessive calcineurin-inhibitor exposure should be considered first, but normal imaging does not exclude rejection or other microscopic disease. The discriminating clue is sustained dysfunction without an adequate explanation. Histology can separate diagnoses whose treatments would otherwise point in opposite directions.
Apply it
Creatinine rises over several days despite corrected hydration, a satisfactory drug level and unobstructed ultrasound findings. You obtain a graft biopsy to direct treatment rather than choosing between more or less immunosuppression from creatinine alone.
Common pitfall: Empirical steroid treatment can obscure diagnosis, while automatic immunosuppression reduction may worsen rejection. Normal Doppler findings exclude neither immune injury nor other parenchymal disease.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
28.Why do calcineurin inhibitors require therapeutic monitoring?
Calcineurin inhibitors have a narrow balance between insufficient immunosuppression and toxicity. Exposure varies with absorption, metabolism, interacting medicines and illness, so the prescribed dose alone does not establish the biological effect. The 2009 KDIGO guideline supports concentration monitoring, including after medication or clinical changes that may alter levels. A correctly timed sample is essential for interpretation. Rising creatinine with a high concentration supports concern for toxicity, but concentration results must still be integrated with the broader graft assessment.
Apply it
A recipient starts an interacting medicine and subsequently develops tremor and rising creatinine. You establish dose timing, obtain the appropriate calcineurin-inhibitor concentration and review the interaction before changing treatment under the transplant team's plan.
Common pitfall: A concentration drawn at the wrong time can mislead. Neither a therapeutic result nor a high result independently proves the cause of graft dysfunction.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
29.How do cellular and antibody-mediated rejection differ?
T-cell-mediated rejection involves lymphocyte-driven injury, characteristically interstitial inflammation and tubulitis, with intimal arteritis in vascular forms. Antibody-mediated rejection involves antibody-associated endothelial injury, often with glomerulitis and peritubular capillaritis; chronic injury may include transplant glomerulopathy. Classification uses current Banff criteria to integrate biopsy morphology, evidence of antibody-endothelium interaction and donor-specific antibody assessment. C4d negativity does not exclude every antibody-mediated phenotype, and cellular and antibody-mediated injury can coexist. Cellular rejection is commonly treated with corticosteroids, with lymphocyte-depleting treatment for selected severe or resistant cases. Appropriate active antibody-mediated phenotypes may require plasma exchange and intravenous immunoglobulin alongside optimisation of immunosuppression. Evidence for effective treatment of chronic antibody-mediated rejection is substantially weaker.
Apply it
A biopsy shows tubulitis together with microvascular inflammation and donor-specific antibodies. You assess for mixed rejection and distinguish active from chronic injury before selecting cellular and antibody-directed treatment components.
Common pitfall: Neither donor-specific antibodies alone nor C4d alone completes the diagnosis. Applying an active antibody-removal regimen indiscriminately to advanced chronic injury overstates the treatment evidence.
30.Why does CMV donor-recipient status influence prevention?
A CMV-seronegative recipient receiving an organ from a seropositive donor lacks prior immunity to a virus potentially carried by the graft. This combination creates a different risk profile from transplantation into a previously exposed recipient. Prevention and monitoring therefore use donor-recipient serostatus together with the intensity of immunosuppression and renal function. The 2009 KDIGO recipient guideline establishes this risk-based principle. Drug choice, adjustment and current programme protocols require attention rather than a uniform plan for every recipient.
Apply it
A CMV-negative kidney recipient receives a CMV-positive organ and later needs intensified immunosuppression. You reassess the prevention and monitoring plan using both the original serological mismatch and the additional immune suppression.
Common pitfall: A symptom-free early postoperative course does not remove CMV risk. Prevention decisions cannot be based solely on the recipient's current symptoms or donor status alone.
KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Pancreas transplantationnot stated
31.When is simultaneous pancreas-kidney transplantation considered?
Simultaneous pancreas-kidney transplantation addresses insulin-treated diabetes and sufficiently advanced kidney disease in an appropriately selected candidate. The kidney and whole-pancreas grafts come from the same deceased donor and are implanted in one operation. Assessment must consider the combined operation's risks, cardiovascular fitness and alternatives for diabetes and renal replacement. The defining distinction is simultaneous treatment of endocrine and renal failure, rather than assuming that every person with diabetes and any reduction in kidney function should undergo the procedure.
Apply it
A person with insulin-treated diabetes and kidney failure is assessed for transplantation. You compare the benefits and operative demands of a simultaneous procedure with kidney transplantation and diabetes management alternatives through the multidisciplinary team.
Common pitfall: The presence of diabetes alone does not establish an indication for a combined transplant. SPK also does not describe two separate operations using unrelated donors.
Cambridge University Hospitals — Combined kidney and pancreas transplant information · NHS Blood and Transplant — Who is able to have a pancreas transplant?
32.How does pancreas-after-kidney transplantation change planning?
Pancreas-after-kidney transplantation adds a pancreas at a later operation to a recipient who already has a kidney transplant. It permits a sequential pathway, potentially including a prior living-donor kidney, but requires reassessment of current kidney function, operative fitness and diabetes-related benefit. The existing kidney graft and its immunosuppressive treatment are important parts of the new evaluation. The defining feature is sequence, rather than an assumption that the pancreas and kidney must share a donor or implantation date.
Apply it
A recipient with a functioning living-donor kidney remains troubled by severe diabetes instability. You assess whether a later pancreas transplant offers sufficient benefit and how its operation and treatment could affect the existing kidney graft.
Common pitfall: Previous kidney transplantation does not automatically establish suitability for a pancreas. The sequential pathway requires a fresh benefit-risk assessment and protection of the functioning renal graft.
NHS Blood and Transplant — Who is able to have a pancreas transplant?
33.Which diabetes problems can justify pancreas transplantation alone?
Pancreas transplantation alone may be considered for selected people whose insulin-treated diabetes remains exceptionally difficult to manage, particularly with severe hypoglycaemia or impaired awareness despite appropriate treatment. Adequate renal assessment matters because the procedure does not replace kidney function, and immunosuppression has its own risks. The decision weighs dangerous metabolic instability against major surgery and lifelong treatment. Insulin use or an elevated glucose measurement by itself does not establish that this balance favours whole-organ transplantation.
Apply it
A person with preserved kidney function experiences recurrent severe hypoglycaemia despite specialist diabetes care. You discuss whole-pancreas and islet assessment, focusing on the severity of events, prior treatment and the burdens of transplantation.
Common pitfall: Transplantation is not justified merely to avoid injections. Preserved renal function also requires protection when considering the consequences of surgery and ongoing immunosuppression.
NHS Blood and Transplant — Who is able to have a pancreas transplant?
34.How does islet transplantation differ from whole-pancreas transplantation?
Islet transplantation separates insulin-producing cells from the donor pancreas and delivers them into the portal venous circulation within the liver. It therefore avoids implantation of a whole pancreas and its donor duodenal segment. Selection considers metabolic benefit and procedural suitability; lower operative burden does not make the treatment risk-free or remove immunological issues. The distinguishing anatomical cue is intraportal cellular implantation, rather than a new pancreatic organ with an enteric exocrine-drainage connection.
Apply it
A candidate with severe diabetes instability is considered poorly suited to a major whole-organ operation. You explain why islet assessment may be relevant and distinguish its liver-directed cell infusion from abdominal implantation of a pancreas graft.
Common pitfall: Islets are not implanted as a small whole pancreas. A less extensive procedure does not establish guaranteed insulin independence or eliminate the need for transplant follow-up.
NHS Blood and Transplant — Who is able to have a pancreas transplant?
35.Why is the native pancreas usually retained?
A whole-pancreas graft is generally placed in the abdominal cavity without removing the recipient's native pancreas. The operation supplies functioning donor endocrine tissue rather than routinely excising the native organ. NHSBT describes transplantation with a short donor duodenal segment connected to the recipient's small intestine or sometimes bladder. Recognising both the retained native organ and the graft is important when interpreting imaging, planning further surgery and localising postoperative pathology to the correct anatomical structure.
Apply it
A postoperative scan identifies both a native pancreas and an abdominal pancreas graft. You explain that this is expected anatomy and direct assessment of a nearby collection toward the graft and its donor-duodenal connection.
Common pitfall: Assuming that transplantation requires native pancreatectomy misreads normal postoperative anatomy and may lead to incorrect localisation of symptoms or imaging abnormalities around the graft.
36.Why does a whole-pancreas graft need exocrine drainage?
A whole pancreas produces digestive secretions as well as hormones. The donor duodenal segment provides a route through which exocrine secretions can drain into the recipient's intestine in an enterically drained transplant. Endocrine secretion reaches the circulation through the graft's venous drainage. These are separate pathways, so normal glucose control does not establish that the enteric connection is intact. A leak can cause serious intra-abdominal infection despite continuing insulin production by viable graft tissue.
Apply it
A recipient maintains good glucose control but develops fever and a collection near the donor duodenum. You investigate an exocrine or enteric leak rather than dismissing a graft complication because insulin production appears satisfactory.
Common pitfall: Endocrine success does not prove exocrine-drainage integrity. A functioning pancreas can coexist with a dangerous donor-duodenal leak requiring prompt assessment and source control.
NHS Blood and Transplant — Pancreas transplant surgery · Preserving the Pancreas Graft: Outcomes of Surgical Repair of Duodenal Leaks in Enterically Drained Pancreas Allografts
37.How does graft venous drainage differ from enteric drainage?
Venous drainage carries blood away from the pancreas graft, including newly secreted insulin. Enteric drainage carries pancreatic digestive secretions through the donor duodenum into bowel. The 2024 single-centre cohort describes systemic venous drainage to the vena cava alongside enteric drainage to a jejunal limb. This demonstrates two distinct reconstructions rather than a universal requirement for one centre's technique. Venous obstruction threatens graft perfusion; disruption of the enteric route creates leakage and contamination.
Apply it
An operative report describes systemic venous drainage and a duodenojejunal anastomosis. You identify the first as the blood-outflow reconstruction and the second as the digestive-secretion route when interpreting a postoperative complication.
Common pitfall: The term drainage can refer to different systems. Confusing venous outflow with exocrine drainage obscures whether the problem threatens perfusion, enteric integrity or both.
38.How does an arterial Y graft reconstruct whole-pancreas inflow?
A common bench reconstruction uses a donor iliac arterial bifurcation as a Y graft. Its two limbs are joined to the graft's superior mesenteric and splenic arteries, and its common stem provides one recipient arterial inflow connection. TSANZ surgical guidance explicitly describes this reconstruction and the need to preserve the common, internal and external iliac arterial segments with an intact bifurcation. The superior mesenteric system supplies the pancreatic head and donor duodenum through pancreaticoduodenal branches, while splenic arterial branches supply much of the body and tail. Both territories need reliable perfusion. Limb length and orientation must avoid tension, twisting and kinking when the pancreas reaches its final position; this is a common technique rather than the only possible reconstruction.
Apply it
During bench preparation, you identify both arterial ends, plan the iliac Y-graft limbs and check their lie in the intended graft orientation. After reperfusion, assess head, duodenal and body-tail perfusion rather than judging success from a pulse in the common stem alone.
Common pitfall: A patent common inflow does not exclude obstruction of one Y-graft limb. Perfusion of the body and tail cannot establish adequate blood supply to the donor duodenum.
TSANZ_SurgicalTechniqueForDeceasedDonorABDO_Version-11_02FINAL.pdf
39.How should new hyperglycaemia after pancreas transplantation be interpreted?
New hyperglycaemia is evidence that metabolic control has changed, not a diagnosis of rejection by itself. Assessment considers graft perfusion, inflammatory or infectious complications, medication effects and immune injury. Timing, associated pain, enzyme trends and imaging help discriminate urgent surgical problems from other explanations. The UEMS curriculum includes laboratory assessment, imaging and pancreatic graft biopsy. Treatment should follow the likely mechanism, with tissue assessment when appropriate after important technical and infectious explanations have been addressed.
Apply it
A recipient develops rising glucose and abdominal discomfort soon after transplantation. You assess graft circulation and associated inflammatory findings before deciding whether the problem is vascular, inflammatory, infectious, pharmacological or immunological.
Common pitfall: Automatically increasing immunosuppression for hyperglycaemia can delay treatment of thrombosis or infection. Equally, one satisfactory glucose reading does not exclude an evolving graft complication.
Transplant Surgery Curriculum · Evolving Trends in the Management of Duodenal Leaks After Pancreas Transplantation: A Single-Centre Experience
40.How do vascular extent and graft perfusion guide management of pancreas graft thrombosis?
Contrast-enhanced CT with arterial and portal venous phases defines thrombus extent, residual flow and graft enhancement. Hakeem and colleagues’ retrospective Cambridge study distinguished peripheral thrombosis confined to a distal branch at the transected margin, intermediate non-occlusive thrombosis, and central occlusive thrombosis. Their proposed algorithm omitted therapeutic anticoagulation for grade 1 venous and grade 1–2 arterial thrombosis, but recommended it for grade 2 venous thrombosis. These are study-derived proposals, not universal rules. Preserved enhancement and clinical stability support conservative management with surveillance; central occlusion with threatened perfusion requires urgent consideration of thrombectomy, anastomotic revision or selected endovascular treatment.
Apply it
A stable recipient with a small distal venous thrombus, patent main outflow and preserved enhancement may receive conservative treatment with repeat imaging. Main portal-vein occlusion, poor enhancement and rising lactate instead demand urgent intervention assessment. A viable graft may be salvageable; established necrosis or uncontrolled graft-related sepsis favours graft pancreatectomy.
Common pitfall: The presence of thrombus alone does not establish graft non-viability. Conversely, worsening pain, hyperglycaemia, acidosis or haemodynamic instability should override reassurance from a previously limited thrombus. Anticoagulation also carries postoperative bleeding risk.
Transplant Surgery Curriculum · Evolving Trends in the Management of Duodenal Leaks After Pancreas Transplantation: A Single-Centre Experience · PMC5763322.pdf
41.How should graft pancreatitis be distinguished from vascular, enteric and immune injury?
Pancreatic inflammation produces acinar injury, enzyme release and graft oedema. Early ischaemia-reperfusion injury can contribute, but raised amylase or lipase does not establish its cause or severity. Assess clinical stability, graft perfusion and cross-sectional imaging for oedema, necrosis and collections. A donor-duodenal leak may also produce enzyme elevation, especially with fever and adjacent gas or fluid. Persistent unexplained inflammation after structural and infectious assessment warrants consideration of biopsy for rejection. Management of uncomplicated inflammation includes supportive care, while thrombosis, necrosis or contamination changes the treatment priority.
Apply it
A recipient has pain and elevated lipase. You establish whether imaging shows an oedematous but perfused graft, vascular compromise, necrosis or a gas-containing periduodenal collection before choosing supportive care, further tissue assessment or urgent intervention.
Common pitfall: An enzyme concentration does not distinguish sterile inflammation from rejection or leakage. Calling the process pancreatitis should begin a causal assessment rather than end it.
Transplant Surgery Curriculum · Evolving Trends in the Management of Duodenal Leaks After Pancreas Transplantation: A Single-Centre Experience
42.How do leak anatomy, tissue viability and sepsis determine pancreas graft salvage?
Leaks can arise from either donor-duodenal staple line, the remaining duodenal segment or the duodenoenteric anastomosis. An intact anastomosis therefore does not exclude leakage. Localisation, perfusion and tissue quality determine whether drainage or operative repair can control the source. The 2017 and 2024 cohorts describe preservation in selected stable recipients with viable grafts and contained contamination. Septic shock, diffuse peritonitis, nonviable duodenum or an irreparable defect favour graft pancreatectomy when preservation cannot provide effective source control.
Apply it
A stable recipient with a viable graft and a localised drainable collection may undergo graft-preserving source control with explicit reassessment. At exploration for deteriorating sepsis, inspect both staple lines and the anastomosis; necrotic, non-repairable tissue changes the decision toward removal.
Common pitfall: Neither normal glucose nor an intact bowel anastomosis establishes safety. Conversely, a duodenal leak alone does not mandate removal if viable tissue and effective source control permit preservation.
Preserving the Pancreas Graft: Outcomes of Surgical Repair of Duodenal Leaks in Enterically Drained Pancreas Allografts · Evolving Trends in the Management of Duodenal Leaks After Pancreas Transplantation: A Single-Centre Experience
43.Which tissue findings distinguish cellular from antibody-mediated pancreas rejection?
T-cell-mediated pancreas rejection features septal inflammation, venulitis, ductitis and mononuclear acinar inflammation; severe disease may include confluent acinar necrosis or arteritis. The [Banff 2022 pancreas report](https://doi.org/10.1016/j.ajt.2023.10.011) specifies three components for antibody-mediated rejection: circulating donor-specific antibodies, morphological evidence of active tissue injury, and interacinar capillary C4d positivity involving at least 1% of the acinar lobular surface. Injury includes capillaritis, acinar damage, vasculitis or thrombosis. All three components support active antibody-mediated rejection; two support probable active antibody-mediated rejection. Mixed rejection requires evidence of both cellular and antibody-mediated processes.
Apply it
Donor-specific antibodies and biopsy-proven capillaritis with acinar injury, but negative C4d, support probable active antibody-mediated rejection. Review biopsy adequacy, staining, antibody results and competing causes of injury. Concurrent diagnostic ductitis or venulitis also warrants assessment for a cellular component.
Common pitfall: C4d-negative injury neither automatically excludes antibody-mediated rejection nor establishes confirmed active rejection. Antibodies alone are insufficient. A kidney biopsy cannot substitute for pancreas assessment: paired biopsies demonstrate discordance in both the presence and type of rejection.
44.How does the pancreas rejection phenotype change treatment?
Biopsy-defined mechanism and severity guide treatment. In the paired-biopsy study, cellular rejection was treated with corticosteroid pulses, with lymphocyte-depleting therapy added according to severity. Antibody-mediated rejection was treated with antibody-directed components including plasma exchange and intravenous immunoglobulin; mixed rejection required treatment of both cellular and antibody-associated injury. These are reported centre protocols rather than universal dose schedules. Assess adherence and baseline immunosuppression, and exclude infection and structural complications before escalation. Follow biochemical and metabolic response without assuming that improved enzymes prove complete histological resolution.
Apply it
The kidney biopsy shows cellular rejection while the pancreas biopsy shows antibody-mediated injury. You recognise why a corticosteroid-only plan based on the kidney could leave an important pancreatic mechanism untreated.
Common pitfall: The label rejection does not justify one regimen for both organs. Escalating immunosuppression during uncontrolled infection or contamination can worsen the competing problem.
45.Why must pancreas and kidney grafts be assessed independently?
The organs share systemic exposures but can reject independently and can have different rejection mechanisms. In the retrospective paired-biopsy study, 15 of 40 selected biopsy pairs were discordant for rejection, including ten with pancreas-only rejection. Among eleven pairs with rejection in both organs, four differed in rejection type. These findings demonstrate that renal histology is an imperfect surrogate for pancreatic histology; the selected cohort does not estimate rejection prevalence in every SPK recipient. Persistent pancreatic abnormalities warrant pancreas-specific assessment even when renal findings are reassuring.
Apply it
An SPK recipient has persistent pancreatic enzyme elevation but unchanged creatinine. After excluding major vascular and enteric problems, you pursue pancreas-specific assessment and biopsy when indicated rather than using the kidney result to rule out pancreatic immune injury.
Common pitfall: A normal kidney biopsy cannot exclude pancreas rejection, and rejection in both organs need not have the same mechanism. Pancreatic enzyme elevation nevertheless remains nonspecific.
Liver transplantationnot stated
46.How does the trajectory of liver failure affect transplant assessment?
Acute liver failure combines acute hepatic injury, coagulopathy, typically INR at least 1.5, and hepatic encephalopathy, usually without pre-existing cirrhosis. Acute decompensation of cirrhosis presents with ascites, encephalopathy or gastrointestinal bleeding; these complications alone do not establish acute-on-chronic liver failure (ACLF). EASL's 2023 ACLF guideline applies the EASL-CLIF framework. Organ-failure thresholds are bilirubin at least 12 mg/dL; creatinine at least 2 mg/dL or renal replacement therapy; West Haven grade III–IV encephalopathy; INR at least 2.5; vasopressor requirement; or PaO2/FiO2 at most 200 or SpO2/FiO2 at most 214. ACLF grade 1 includes isolated kidney failure; one liver, coagulation, circulatory or respiratory failure with creatinine 1.5–1.9 mg/dL and/or grade I–II encephalopathy; or isolated cerebral failure with creatinine 1.5–1.9 mg/dL. Two organ failures define grade 2; three or more define grade 3.
Apply it
A patient with cirrhosis, new ascites, grade II encephalopathy, bilirubin 8 mg/dL, INR 1.8 and creatinine 1.0 mg/dL, with preserved circulation and oxygenation, has acute decompensation without ACLF. If creatinine rises to 2.4 mg/dL and vasopressors become necessary, two organ failures establish ACLF grade 2. By comparison, acute hepatic injury with INR 2.0 and new encephalopathy in a previously non-cirrhotic patient suggests acute liver failure. Treat precipitants and repeat organ-failure assessment daily. Recovery of circulation with persistent kidney failure changes ACLF grade 2 to grade 1 and may improve the transplant window; additional respiratory failure changes it to grade 3 and demands renewed assessment of urgency and operative benefit.
Common pitfall: Encephalopathy occurs in all three settings and cannot classify the syndrome alone. Coagulopathy in established cirrhosis does not convert decompensation into acute liver failure. Count failures using the specified thresholds and grade-1 combinations. Severe ACLF warrants urgent transplant evaluation, but candidacy depends on serial reversibility, infection control and expected post-transplant survival.
EASL Clinical Practice Guidelines on liver transplantation, 2024 · EASL%20Clinical%20Practice%20Guidelines%20on%20acute-on-chronic%20liver%20failure.pdf
47.How should frailty influence liver transplant selection?
Frailty reflects impaired physiological reserve and reduced ability to withstand stress; it is related to, but distinct from, reduced muscle mass. EASL recommends assessing frailty in candidates with cirrhosis using objective, repeatable measures. Frailty alone should not be a contraindication to transplantation. Instead, it informs risk discussion, monitoring, rehabilitation and nutritional support. The discriminating clue is potentially modifiable vulnerability, which should be measured over time rather than converted into an automatic exclusion based on appearance or chronological age.
Apply it
A candidate has poor functional performance despite a moderate laboratory severity score. You document objective frailty measures, arrange nutritional and rehabilitation assessment, and review progress while continuing the broader transplant evaluation.
Common pitfall: A laboratory score does not measure functional reserve. Equally, identifying frailty does not justify automatic exclusion without examining its severity, trajectory and opportunities for improvement.
EASL Clinical Practice Guidelines on liver transplantation, 2024
48.Why does HCC selection require tumour biology as well as size?
Tumour burden and tumour biology provide complementary information about recurrence risk after liver transplantation. Meeting a size-and-number framework does not make a markedly elevated alpha-fetoprotein irrelevant. EASL 2024 advises against transplantation for unresectable HCC presenting with AFP above 1,000 ng/mL unless liver-directed treatment produces a significant, sustained and persistent decline. Actual selection also follows the relevant allocation system. The important cue is discordance between apparently favourable imaging burden and adverse biological behaviour.
Apply it
A candidate's HCC fits the programme's morphological limits, but AFP remains 1,400 ng/mL without treatment response. You seek biological risk reassessment rather than regarding the imaging measurements as sufficient grounds to proceed.
Common pitfall: Acceptable tumour dimensions do not erase adverse biology. The AFP finding also does not mean every patient is permanently excluded regardless of a sustained treatment response.
EASL Clinical Practice Guidelines on liver transplantation, 2024
49.When can HCC downstaging reopen transplant consideration?
EASL supports considering selected patients initially beyond Milan criteria when liver-directed treatment downstages disease to the accepted criteria of the relevant allocation system. Macrovascular tumour invasion and extrahepatic spread are important boundaries. Selection also considers the durability of response and biological markers rather than only the latest tumour measurement. Downstaging therefore tests both reduction of visible burden and behaviour over time. It is a route to reassessment, not an automatic allocation entitlement after any radiological shrinkage.
Apply it
A patient initially outside accepted tumour limits has a durable response to liver-directed therapy, falling AFP and no macrovascular invasion or extrahepatic disease. You reassess against the country's allocation criteria rather than assuming initial ineligibility is permanent.
Common pitfall: One smaller scan does not establish durable favourable biology. Downstaging also does not override macrovascular tumour invasion, metastatic disease or the applicable allocation rules.
EASL Clinical Practice Guidelines on liver transplantation, 2024
50.How do graft quality and recipient demand interact?
Adequate liver volume does not ensure adequate functional reserve. Donor hypoperfusion and circulatory arrest cause warm ischaemic injury; subsequent cold preservation and reperfusion can add hepatocellular dysfunction and biliary injury. Injured tissue therefore contributes less effective metabolic and synthetic capacity despite remaining within the measured graft volume. For controlled-DCD transplantation, EASL identifies donor age over 60 years, donor warm ischaemia over 30 minutes, graft cold ischaemia over six hours, recipient MELD over 25 and retransplantation as adverse factors. These are risk factors rather than automatic exclusion thresholds; their accumulation makes size-based acceptance particularly unsafe.
Apply it
Consider a whole liver from a 68-year-old controlled-DCD donor with 35 minutes of donor warm ischaemia and projected eight-hour cold preservation for a recipient with MELD 32 receiving renal replacement therapy. Verify the ischaemic intervals and minimise further cold time. A yellow, rounded or unusually firm graft warrants biopsy to quantify steatosis and assess underlying pathology. Substantial macrosteatosis would add concern and favour reconsidering this pairing. Perfusion preservation with viability assessment may provide further evidence before acceptance or discard.
Common pitfall: Avoid combining several adverse graft features with a recipient poorly able to tolerate initial dysfunction merely because graft size is sufficient. Conversely, one donor risk factor does not mandate discard: compare the proposed pairing with the recipient’s risk of continued waiting.
EASL Clinical Practice Guidelines on liver transplantation, 2024 · Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation · TSANZ_SurgicalTechniqueForDeceasedDonorABDO_Version-11_02FINAL.pdf
51.Which segments form the usual adult-child split liver grafts?
The conventional adult-child split commonly provides a left lateral section comprising segments II and III for a child and an extended right graft for an adult. This differs from simply dividing the liver into two equal halves. Planning must preserve suitable inflow, outflow and biliary drainage for both grafts. EASL and NHSBT describe splitting as a way to serve more recipients, while recognising added technical and complication considerations. Anatomical labels must match the actual segmental allocation.
Apply it
A team plans an adult-child split from one deceased donor. You identify segments II and III as the proposed paediatric graft and map the vessels and ducts needed by the remaining adult graft before division.
Common pitfall: Left lateral section and full left lobe are not interchangeable terms. A segmental division is safe only when both resulting grafts retain workable vascular and biliary anatomy.
EASL Clinical Practice Guidelines on liver transplantation, 2024 · NHS Blood and Transplant — Types of liver transplant
52.Why does living liver donation require two-sided volume planning?
Living liver donation must leave an adequate, safely perfused and drained remnant for the donor while providing a suitable graft for the recipient. Recipient need cannot be met simply by taking progressively more liver. Imaging assesses volumes together with arterial, portal, venous and biliary anatomy, because volume without viable drainage and inflow is misleading. The operative decision protects donor safety and recipient function simultaneously, using a multidisciplinary evaluation rather than a universal percentage applied without clinical context.
Apply it
A proposed larger graft would improve recipient volume but leave a concerning donor remnant. You reassess graft choice and alternative pathways rather than accepting increased donor risk solely to meet the recipient's preferred graft size.
Common pitfall: A favourable recipient graft estimate does not establish donor safety. Volume calculations also cannot compensate for an undrained or inadequately perfused remnant segment.
EASL Clinical Practice Guidelines on liver transplantation, 2024
53.How do piggyback and conventional caval reconstruction differ?
In conventional liver transplantation, removal of the native liver includes its retrohepatic vena cava, which is replaced with the donor caval segment. A piggyback approach preserves the recipient vena cava and constructs graft hepatic venous drainage into the retained outflow system. The original randomised trial compares these reconstructive approaches. The defining difference is recipient caval preservation, rather than whether the liver graft occupies the native hepatic position. Outflow adequacy remains essential whichever reconstruction is chosen.
Apply it
An operative description states that the recipient retrohepatic vena cava remains in place and the graft outflow is joined to the retained venous system. You identify a piggyback reconstruction and review the outflow geometry accordingly.
Common pitfall: Piggyback does not mean retention of the whole native liver. Both conventional and piggyback procedures can place the graft orthotopically while using different caval reconstructions.
54.What makes a liver transplant orthotopic or auxiliary?
Orthotopic describes placement in the liver's anatomical region, whereas auxiliary describes implantation with native liver tissue retained. These terms address different features and can overlap in auxiliary partial orthotopic transplantation. The original auxiliary living-donor series confirms that functioning native liver can remain alongside the graft. Consequently, orthotopic should not be defined as necessarily requiring complete removal of all native liver tissue. The distinction matters when interpreting operative descriptions, residual function and the contributions of native and donor tissue.
Apply it
A report describes a partial donor liver implanted in the hepatic region while functioning native liver remains. You recognise the auxiliary and orthotopic features together rather than treating those terms as mutually exclusive operation types.
Common pitfall: Anatomical position and native-liver retention are separate descriptors. Assuming that every orthotopic transplant removes all native tissue overlooks established auxiliary partial orthotopic procedures.
55.How is primary non-function distinguished from recoverable early dysfunction?
Primary non-function is catastrophic, irreversible graft failure after transplantation, rather than a synonym for any early biochemical abnormality. Evaluation examines synthetic and metabolic failure and excludes identifiable technical and immunological explanations. Severe coagulopathy, persistent lactate problems and worsening clinical instability are more concerning than an isolated transaminase peak. The original clinical study emphasises early recognition and reoperation decisions. Potentially recoverable early dysfunction requires close support and reassessment, while suspected irreversible failure demands urgent consideration of retransplantation.
Apply it
A recipient has worsening coagulopathy, hypoglycaemia and persistent acidosis despite support. Vascular assessment and investigation find no correctable technical or immunological cause. You urgently evaluate irreversible graft failure and retransplantation rather than relying on transaminase trends alone.
Common pitfall: A high aminotransferase concentration alone does not establish primary non-function. Conversely, waiting for biochemical certainty during progressive metabolic collapse can lose a retransplantation opportunity.
Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation
56.Why can hepatic artery occlusion cause biliary injury?
The transplanted biliary tree depends critically on its hepatic arterial supply. Arterial occlusion can therefore cause bile-duct ischaemia, leakage or non-anastomotic stricturing even when portal venous flow persists. The original cholangiographic study links hepatic arterial occlusion with biliary injury. This mechanism explains why apparent biliary disease may require investigation of arterial inflow rather than treatment focused only on the duct. A patent portal vein is reassuring for one vascular system but does not protect the ducts equivalently.
Apply it
A liver recipient develops biliary abnormalities and unexplained graft-test changes. Although portal flow is present, you assess hepatic arterial patency because an arterial lesion could explain both the duct injury and the biochemical deterioration.
Common pitfall: Portal perfusion does not establish adequate biliary perfusion. Labelling a stricture as purely anastomotic without considering arterial injury can miss the underlying mechanism.
Cholangiographic findings in hepatic artery occlusion after liver transplantation
57.How do biliary leaks and strictures create different diagnostic patterns?
A leak allows bile to escape, potentially producing a collection, peritonitis or infection; a stricture impairs drainage and can cause cholestasis or cholangitis. Location and vascular context matter, because an anastomotic problem and diffuse ischaemic duct injury need different interpretation. Assessment integrates imaging, the reconstruction performed and hepatic arterial status. The practical decision is to define whether the dominant problem is leakage, obstruction or a broader ischaemic process before selecting a drainage or reconstructive approach.
Apply it
A recipient has fever, cholestatic tests and abnormal ducts on imaging. You establish the site and pattern of obstruction, review the biliary reconstruction and assess arterial inflow rather than assuming every postoperative duct problem is an isolated anastomotic narrowing.
Common pitfall: Cholestasis does not identify the lesion's location or cause. A focal duct intervention may be insufficient when the underlying process is widespread arterial-associated biliary injury.
EASL Clinical Practice Guidelines on liver transplantation, 2024 · Cholangiographic findings in hepatic artery occlusion after liver transplantation
58.When should abnormal liver tests prompt rejection assessment?
Abnormal graft tests require a differential that includes vascular and biliary complications, infection, drug effects, recurrent disease and rejection. Donor-specific antibodies may contribute to risk assessment but do not independently establish antibody-mediated rejection. EASL supports integrating clinical findings with biopsy when immune injury is suspected, particularly with persistent abnormalities or relevant antibody findings. The discriminating principle is that biochemical change identifies injury, while histological and immunological interpretation helps determine mechanism and avoids inappropriate empirical escalation.
Apply it
A recipient develops persistent graft-test abnormalities after imaging excludes a major vascular or biliary lesion. You review medicines, infection and adherence, then pursue liver biopsy when indicated to establish whether immune injury explains the pattern.
Common pitfall: Neither abnormal transaminases nor detectable donor-specific antibodies alone prove rejection. Increasing immunosuppression without identifying the cause may aggravate infection or overlook a structural complication.
EASL Clinical Practice Guidelines on liver transplantation, 2024
59.How can liver immunosuppression protect renal function without abandoning graft protection?
Calcineurin inhibitors can impair renal function through renal vasoconstriction and cumulative nephrotoxicity. One renal-sparing strategy combines lower tacrolimus exposure with mycophenolate: tacrolimus continues to inhibit T-cell activation while mycophenolate suppresses lymphocyte proliferation, maintaining complementary immune protection during exposure reduction. A separate perioperative strategy uses induction treatment with delayed tacrolimus introduction in selected patients at renal risk, allowing early immunosuppressive cover while limiting immediate calcineurin-inhibitor exposure. Neither approach is equivalent to complete immunosuppression withdrawal. EASL supports individualised regimens with monitoring of renal function, tacrolimus concentrations, graft tests and evidence of rejection.
Apply it
A liver recipient develops renal impairment on tacrolimus. After investigating other renal causes, you consider adding or optimising mycophenolate while reducing tacrolimus exposure under supervision, tracking renal response and graft safety. For a selected perioperative high-risk recipient, induction with delayed tacrolimus is a distinct planning option.
Common pitfall: Reducing tacrolimus without maintaining adequate overall immunosuppression can provoke rejection. Renal dysfunction is not always calcineurin-inhibitor toxicity, and normal liver tests do not establish tolerance permitting complete withdrawal.
EASL Clinical Practice Guidelines on liver transplantation, 2024
60.Why does recurrent disease remain relevant after liver replacement?
Transplantation removes the damaged liver while recipient autoimmune mechanisms can persist. Primary biliary cholangitis (PBC) targets small bile ducts; ursodeoxycholic acid modifies bile composition and limits cholestatic injury. EASL 2024 recommends lifelong ursodeoxycholic acid after transplantation for PBC to prevent recurrence. Autoimmune hepatitis (AIH) involves immune-mediated hepatocyte injury. EASL therefore recommends cautious corticosteroid withdrawal because recurrence can follow reduced immune suppression. This requires balancing recurrence risk against steroid toxicity; it does not mandate lifelong corticosteroids for every AIH recipient.
Apply it
After transplantation for PBC, persistent alkaline phosphatase elevation warrants assessment for recurrence alongside biliary obstruction, vascular complications and rejection, using Doppler ultrasound, appropriate biliary imaging and liver biopsy when needed. After transplantation for AIH, rising aminotransferases and IgG during steroid reduction raise suspicion of recurrence. Review adherence and immunosuppressant exposure, exclude infection and drug injury, and use biopsy to assess recurrent hepatitis and rejection before changing treatment.
Common pitfall: Neither a familiar biochemical pattern nor the original diagnosis proves recurrence. Recurrence and rejection may coexist. Ursodeoxycholic acid for PBC does not replace adequate rejection prophylaxis or the immune suppression needed for AIH.
EASL Clinical Practice Guidelines on liver transplantation, 2024
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- For each selected module, practise moving from donor or recipient findings to an explicit decision, its mechanism and the evidence that would change it.
- Distinguish immediate vascular threats and uncontrolled contamination from problems that permit staged investigation or graft-preserving treatment.
- Draw the coordinated perfusion and venous-venting sequence, shared liver-pancreas arterial variants, kidney vascular and ureteric anatomy, pancreas arterial reconstruction and drainage pathways, and liver split-graft and caval reconstructions.
- Interpret compatibility, drug concentrations, biochemical trends and biopsy findings together rather than treating any single result as a complete diagnosis.
- Keep UK death-determination standards, U.S. PHS surveillance and local allocation rules clearly attributed to their jurisdictions.
- Use the official curriculum to add unsampled depth, including detailed donor management, vascular access, infection and rejection treatment, and disease-specific liver care.
A practical preparation plan
1. Map your selected modules
Read the entire official curriculum for each module you will take. Mark each topic as explainable, applicable to a case, or requiring further study. Use this selective guide to strengthen decisions while maintaining a separate list of curriculum topics it does not cover.
2. Build an anatomy-to-complication map
Draw the relevant inflow, outflow and drainage routes from memory. For every anastomosis or preserved tissue plane, explain the consequence of thrombosis, tension, ischaemia or leakage and identify the first discriminating clinical or imaging finding.
3. Rehearse structured clinical reasoning aloud
Practise stating the leading problem, dangerous alternatives, immediate investigation and treatment threshold. Add a brief explanation of consent, donor safety or multidisciplinary communication where relevant. Use timed discussions to build clear reasoning for examiner-led stations.
4. Complete and analyse the learning questions
Answer the 20 questions without notes, then explain why each alternative is less appropriate. Record whether an error arose from anatomy, mechanism, interpretation or prioritisation, and revisit the relevant source rather than memorising an answer position.
5. Use spaced recall and fresh cases
Review the flashcards repeatedly, then change one feature in each case, such as graft viability, haemodynamic stability, antibody findings or arterial patency. Explain how that change alters the decision. Complete remaining curriculum gaps before relying on repeated success with these drills.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Transplant Surgery EBSQ Examinations
- Transplant Surgery Curriculum
- EAU Renal Transplantation Guidelines — Summary of Changes
- EAU Guidelines on Renal Transplantation — The Guideline
- KDIGO Living Kidney Donor
- Summary of KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
- KDIGO 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients
- Assessing Solid Organ Donors and Monitoring Transplant Recipients for HIV, HBV, and HCV Infection — U.S. Public Health Service Guideline, 2020
- Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
- Cambridge University Hospitals — Combined kidney and pancreas transplant information
- NHS Blood and Transplant — Who is able to have a pancreas transplant?
- NHS Blood and Transplant — Pancreas transplant surgery
- Preserving the Pancreas Graft: Outcomes of Surgical Repair of Duodenal Leaks in Enterically Drained Pancreas Allografts
- EASL Clinical Practice Guidelines on liver transplantation, 2024
- Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation
- Prospective Randomized Trial Comparing Hepatic Venous Outflow and Renal Function after Conventional versus Piggyback Liver Transplantation
- NHS Blood and Transplant — Types of liver transplant
- A Code of Practice for the diagnosis and confirmation of death: 2025 update
- Evolving Trends in the Management of Duodenal Leaks After Pancreas Transplantation: A Single-Centre Experience
- Cholangiographic findings in hepatic artery occlusion after liver transplantation
- Auxiliary partial orthotopic living donor liver transplantation as an aid for small-for-size grafts in larger recipients
- Cholangiographic Findings in Hepatic Artery Occlusion After Liver Transplantation - PMC
- TSANZ_SurgicalTechniqueForDeceasedDonorABDO_Version-11_02FINAL.pdf
- Current Reference Guide to the Banff Classification - BANFF
- Introduction - EAU Guidelines on Renal Transplantation - Uroweb
- EAU-Guidelines-on-Renal-Transplantation-2026.pdf
- EASL%20Clinical%20Practice%20Guidelines%20on%20acute-on-chronic%20liver%20failure.pdf
- Arterial Blood Supply of Liver Segment IV and Its Possible Surgical Consequences - PMC
- PMC5763322.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.